News Novartis to develop digital therapies with Pear Deal covers digital therapies for MS and schizophrenia
News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Boehringer collaborates with Autifony on schizophrenia drug Deal could be worth 627.5 million euros
News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News Lundbeck/Otsuka look for new use of mental health drug Companies want new bipolar disorder use for Abilify Maintena.
News Janssen's quarterly schizophrenia drug approved in EU Company hopes new formulation will improve patient outcomes.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
